<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03167242</url>
  </required_header>
  <id_info>
    <org_study_id>CKAF156A2202</org_study_id>
    <secondary_id>2020-003284-25</secondary_id>
    <nct_id>NCT03167242</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria</brief_title>
  <official_title>A Phase 2 Interventional, Multicenter, Randomized Open Label Study to Determine the Effective and Tolerable Dose of KAF156 and Lumefantrine Solid Dispersion Formulation in Combination, Given Once Daily for 1, 2 and 3-days to Adults and Children With Uncomplicated Plasmodium Falciparum Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the most effective and tolerable dose at the shortest dosing&#xD;
      regimen of the investigational drug KAF156 in combination with a solid dispersion formulation&#xD;
      of lumefantrine (LUM-SDF) in adult/adolescent and pediatric patients with uncomplicated P.&#xD;
      falciparum malaria.&#xD;
&#xD;
      There is unmet medical need for anti-malarial treatment with new mechanism of action to&#xD;
      reduce probability of developing resistance, and for duration shorter than 3 days of&#xD;
      treatment and/or reduced pill burden.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2, 2017</start_date>
  <completion_date type="Actual">June 28, 2021</completion_date>
  <primary_completion_date type="Actual">June 14, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PCR-corrected adequate clinical and parasitological response (ACPR)</measure>
    <time_frame>Day 28 post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE) incidence and severity, liver and kidney function tests and electrocardiogram (ECG) abnormalities</measure>
    <time_frame>Up to Day 42 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCR-uncorrected ACPR</measure>
    <time_frame>Days 14, 28 and 42 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCR-corrected ACPR</measure>
    <time_frame>Days 14 and 42 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of recrudescence and reinfection</measure>
    <time_frame>Days 14, 28 and 42 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite and fever clearance times</measure>
    <time_frame>Up to Day 42 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with parasitaemia</measure>
    <time_frame>12, 24 and 48 hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Peak Observed Concentration (Cmax)</measure>
    <time_frame>Up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>Up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time after administration of a drug when the maximum plasma concentration is reached (Tmax)</measure>
    <time_frame>Up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T½)</measure>
    <time_frame>Up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">484</enrollment>
  <condition>Acute Uncomplicated Plasmodium Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>KAF156 400 mg and LUM-SDF 960 mg once daily (QD) for 1 day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KAF156 800 mg and LUM-SDF 960 mg QD for 1 day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KAF156 400 mg and LUM-SDF 960 mg QD for 2 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KAF156 200 mg and LUM-SDF 480 mg QD for 3 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KAF156 400 mg and LUM-SDF 480 mg QD for 3 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KAF156 400 mg and LUM-SDF 960 mg QD for 3 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coartem twice a day (BID) for 3 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KAF156 200 mg and LUM-SDF 960 mg once daily for 1 day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK Run-in Cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KAF156 and LUM-SDF</intervention_name>
    <description>Exploration of different dose combinations of KAF156 and LUM-SDF. In Part B, up to three arms will be repeated in children 2 to 12 Years to confirm safety and efficacy from Part A.</description>
    <arm_group_label>KAF156 200 mg and LUM-SDF 480 mg QD for 3 days</arm_group_label>
    <arm_group_label>KAF156 200 mg and LUM-SDF 960 mg once daily for 1 day</arm_group_label>
    <arm_group_label>KAF156 400 mg and LUM-SDF 480 mg QD for 3 days</arm_group_label>
    <arm_group_label>KAF156 400 mg and LUM-SDF 960 mg QD for 2 days</arm_group_label>
    <arm_group_label>KAF156 400 mg and LUM-SDF 960 mg QD for 3 days</arm_group_label>
    <arm_group_label>KAF156 400 mg and LUM-SDF 960 mg once daily (QD) for 1 day</arm_group_label>
    <arm_group_label>KAF156 800 mg and LUM-SDF 960 mg QD for 1 day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coartem</intervention_name>
    <description>Control arm</description>
    <arm_group_label>Coartem twice a day (BID) for 3 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Part A: male and female patients ≥ 12 years and with a body weight ≥ 35.0 kg. Part B:&#xD;
             after determining the effective/tolerated doses and regimens in adolescent and adult&#xD;
             patients, male and female patients ≥ 2 and &lt; 12 years and with a body weight ≥ 10.0 kg&#xD;
             will be included.&#xD;
&#xD;
          -  Microscopic confirmation of P. falciparum by Giemsa-stained thick and thin films.&#xD;
&#xD;
          -  P. falciparum parasitaemia of more than 1000 and less than 150 000 parasites/µL at the&#xD;
             time of pre-screening (i.e., Study Visit 1).&#xD;
&#xD;
          -  Axillary temperature ≥ 37.5 ºC or oral/tympanic/rectal temperature ≥ 38.3 ºC; or&#xD;
             similar history of fever during the previous 24 hours (history of fever must be&#xD;
             documented).&#xD;
&#xD;
          -  Written informed consent must be obtained before any assessment is performed. If the&#xD;
             patient is unable to read and write, then a witnessed consent according to local&#xD;
             ethical standards is permitted. Patients &lt; 18 years old, who are capable of providing&#xD;
             assent, must provide assent with parental/legal guardian consent or as per local&#xD;
             ethical guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mixed Plasmodium infections.&#xD;
&#xD;
          -  Signs and symptoms of severe malaria according to WHO (World Health Organization) 2015&#xD;
             criteria unless characterized by high parasitaemia only.&#xD;
&#xD;
          -  Patients with concurrent febrile illnesses (e.g., typhoid fever).&#xD;
&#xD;
          -  Severe vomiting, defined as more than 3 times in the 24 hours prior to inclusion in&#xD;
             the study or severe diarrhea defined as more than 3 watery stools per day.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women.&#xD;
&#xD;
          -  Clinically relevant abnormalities of electrolyte balance which require correction,&#xD;
             e.g., hypokalemia, hypocalcemia or hypomagnesemia.&#xD;
&#xD;
          -  Anemia (Hemoglobin level &lt; 8 g/dL).&#xD;
&#xD;
          -  Patients with prior antimalarial therapy or antibiotics with antimalarial activity&#xD;
             within minimum of their five (5) plasma half-lives (or within 4 weeks of screening if&#xD;
             half-life is unknown).&#xD;
&#xD;
          -  History or family history of long QT syndrome or sudden cardiac death, or any other&#xD;
             clinical condition known to prolong the QTc (heart rate-corrected QT) interval, such&#xD;
             as history of symptomatic cardiac arrhythmias, clinically relevant bradycardia or&#xD;
             severe heart disease.&#xD;
&#xD;
          -  Any surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism, or excretion of drugs, or which may jeopardize the patient&#xD;
             in case of participation in the study. The investigator should make this determination&#xD;
             in consideration of the patient's medical history and/or clinical or laboratory&#xD;
             evidence of any of the following:&#xD;
&#xD;
          -  AST/ALT &gt; 2 x the upper limit of normal range (ULN), regardless of the level of total&#xD;
             bilirubin&#xD;
&#xD;
          -  AST/ALT &gt; 1.5 and ≤ 2 x ULN and total bilirubin is &gt; ULN&#xD;
&#xD;
          -  Total bilirubin &gt; 2 x ULN, regardless of the level of AST/ALT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanoro</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lambarene</city>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ranchi</city>
        <state>Jharkhand</state>
        <zip>834009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kombewa</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siaya</city>
        <zip>2300</zip>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sotuba</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chokwe</city>
        <country>Mozambique</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tak</city>
        <zip>63140</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Masaka</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tororo</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Binh Phuoc Province</city>
        <state>VNM</state>
        <zip>830000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Gabon</country>
    <country>India</country>
    <country>Kenya</country>
    <country>Mali</country>
    <country>Mozambique</country>
    <country>Thailand</country>
    <country>Uganda</country>
    <country>Vietnam</country>
  </location_countries>
  <removed_countries>
    <country>Côte D'Ivoire</country>
    <country>Gambia</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 19, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2017</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artemether, Lumefantrine Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

